Go Pro
→ Your 10X AI demo is starting… (From TradeSmith) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$59.50
+2.4%		$53.05
$44.12
▼
$78.48
$5.62B1.741.52 million shs2.45 million shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
+2.37%+11.11%+25.95%+18.15%+12.12%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$59.50
+2.4%		$53.05
$44.12
▼
$78.48
$5.62B1.741.52 million shs2.45 million shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
+2.37%+11.11%+25.95%+18.15%+12.12%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
2.58
Moderate Buy$68.0614.38% Upside

Current Analyst Ratings Breakdown

Latest CRSP Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/6/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral$55.00
8/4/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$82.00 ➝ $88.00
7/22/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
7/17/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/8/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$80.00
7/6/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Citizens Jmp logo
Citizens Jmp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform$80.00
6/12/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price Target$80.00
6/11/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Morgan Stanley logo
Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Set Price TargetEqual Weight$60.00
5/27/2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingMarket Outperform
(Data available from 8/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
$3.51M1,639.05N/AN/A$18.06 per share3.29
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$581.60M-$4.76N/AN/AN/A-3,368.72%-24.39%-18.25%11/9/2026 (Estimated)

Latest CRSP Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/3/2026Q2 2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
-$1.19-$0.94+$0.25-$0.94$7.45 million$10.18 million
6/30/2026Q2 2026
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/A-$0.94N/A-$0.94N/A$10.18 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
0.34
17.85
17.85

Institutional Ownership

CompanyInstitutional Ownership
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
69.20%

Insider Ownership

CompanyInsider Ownership
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
5.20%
CompanyEmployeesShares OutstandingFree FloatOptionable
CRISPR Therapeutics AG stock logo
CRSP
CRISPR Therapeutics
46096.69 million91.67 millionOptionable

Recent News About These Companies

CRISPR Therapeutics Stock Is Up Only 8% This Year. Is Cathie Wood's Bet on the Gene-Editing Stock Dead Money?
August 21 at 2:20 PM  |  fool.comhttps://www.fool.com/investing/2026/08/21/crispr-therapeutics-stock-is-up-only-8-this-year/
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Recommendation of "Moderate Buy" from Brokerages
August 20 at 2:44 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30971671
CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Recommendation of "Moderate Buy" by Brokerages
August 20 at 2:43 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/crispr-therapeutics-ag-nasdaqcrsp-given-consensus-recommendation-of-moderate-buy-by-brokerages-2026-08-20/
CRISPR Therapeutics (NASDAQ:CRSP) Trading Up 11.2% - Time to Buy?
August 19 at 3:19 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/crispr-therapeutics-nasdaqcrsp-trading-up-112-time-to-buy-2026-08-19/
Bank of America Corp DE Decreases Stock Position in CRISPR Therapeutics AG $CRSP
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-decreases-stock-position-in-crispr-therapeutics-ag-crsp-2026-08-13/
CRISPR Therapeutics AG $CRSP Stock Position Raised by Quantinno Capital Management LP
August 11, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-crispr-therapeutics-ag-crsp-stock-position-raised-by-quantinno-capital-management-lp-2026-08-11/
CRISPR Therapeutics (NASDAQ:CRSP) Rating Increased to Hold at Wall Street Zen
August 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/crispr-therapeutics-nasdaqcrsp-rating-increased-to-hold-at-wall-street-zen-2026-08-08/
Goldman Sachs Keeps Their Hold Rating on Crispr Therapeutics AG (CRSP)
August 7, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/CRSP/pressreleases/3717067/goldman-sachs-keeps-their-hold-rating-on-crispr-therapeutics-ag-crsp/
HC Wainwright Has Positive Forecast for CRSP FY2026 Earnings
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/hc-wainwright-has-positive-forecast-for-crsp-fy2026-earnings-2026-08-07/
Dimensional Fund Advisors LP Sells 412,889 Shares of CRISPR Therapeutics AG $CRSP
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-dimensional-fund-advisors-lp-sells-412889-shares-of-crispr-therapeutics-ag-crsp-2026-08-07/
Brave Asset Management Inc. Cuts Stake in CRISPR Therapeutics AG $CRSP
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-brave-asset-management-inc-cuts-stake-in-crispr-therapeutics-ag-crsp-2026-08-07/
California State Teachers Retirement System Increases Stock Position in CRISPR Therapeutics AG $CRSP
August 7, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-california-state-teachers-retirement-system-increases-stock-position-in-crispr-therapeutics-ag-crsp-2026-08-07/
Crispr Therapeutics AG (CRSP) Receives a Hold from Wells Fargo
August 6, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/CRSP/pressreleases/3690252/crispr-therapeutics-ag-crsp-receives-a-hold-from-wells-fargo/
Equities Analysts Offer Predictions for CRSP Q3 Earnings
August 6, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/equities-analysts-offer-predictions-for-crsp-q3-earnings-2026-08-06/
Piper Sandler Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)
August 5, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/CRSP/pressreleases/3664692/piper-sandler-reaffirms-their-buy-rating-on-crispr-therapeutics-ag-crsp/
CRISPR: "Strong Buy" CASGEVY Sales Growth And In Vivo Expansion With CTX310
August 5, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4930696-crispr-strong-buy-casgevy-sales-growth-and-in-vivo-expansion-with-ctx310
Brokers Offer Predictions for CRSP FY2028 Earnings
August 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/brokers-offer-predictions-for-crsp-fy2028-earnings-2026-08-05/
Crispr Therapeutics Posts "Quiet" Quarter as Casgevy Advances, SiRNA Data Readouts Near, RBC Says
August 4, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/crispr-therapeutics-posts-quiet-quarter-154954836.html
CRISPR Therapeutics' Q2 Earnings & Revenues Surpass Estimates
August 4, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2967651/crispr-therapeutics-q2-earnings-revenues-surpass-estimates?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-2967651
CRISPR Therapeutics (CRSP) Q2 2026
August 3, 2026  |  247wallst.comhttps://www.247wallst.com/companies/crsp/earnings/
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
August 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/crispr-therapeutics-provides-business-reports-201500287.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

CRISPR Therapeutics stock logo

CRISPR Therapeutics NASDAQ:CRSP

$59.50 +1.38 (+2.37%)
As of 08/21/2026 04:00 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas